News

Genzyme said that it will conduct the study in patients with type 1 Gaucher disease at medical centers in Europe, Israel, South America and the US. The open-label

The study is designed to determine if the addition of a radiopharmaceutical to bisphosphonates for patients with asymptomatic or stable symptomatic bone metastasis will delay the time to

The company expects to initiate two phase II studies within the next six months. The trials will have the goal of confirming the mechanism of action of NCX

Xechem Nigeria, which received regulatory approval for Nicosan on July 3rd, 2006 from the National Agency for Food and Drug Administration and Control of Nigeria (NAFDAC), has been

The collaboration will focus on inhibitors of poly (ADP-ribose) polymerase (PARP). PARP is a nuclear enzyme within cells that directs the repair of damaged DNA via the activation

The vaccine, which uses a proprietary adjuvant, enabled over 80% of subjects who received 3.8 micrograms of antigen to demonstrate a strong seroprotective immune response. According to the

As part of the collaboration, Sandoz will make an initial payment of $75 million to Momenta for the purchase of approximately 4.7 million shares at a price of

Avalon will use its proprietary AvalonRx platform to discover new active compounds in screens against selected targets and target pathways. ChemDiv will provide Avalon access to its Discovery

Through this agreement, Asuragen will have access to microRNAs identified by a group led by Rockefeller University researcher Dr Thomas Tuschl. The microRNAs have been found to have